Advertisement

[Correspondence] Pembrolizumab plus chemotherapy for advanced gastric cancer

August, 08, 2024 | Select Oncology Journal Articles

In The Lancet, Yelena Y Janjigian and colleagues1 recently published the results of the interim analyses of the KEYNOTE-811 trial, comparing first-line pembrolizumab plus trastuzumab and chemotherapy with placebo plus trastuzumab and chemotherapy for advanced HER2-positive gastric or gastro-oesophageal junction adenocarcinoma. In The Lancet Oncology, Sun Young Rha and colleagues2 published the final results of the KEYNOTE-859 trial, comparing first-line pembrolizumab plus chemotherapy with placebo plus chemotherapy for advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –

Advertisement

LATEST

Advertisement

Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy